Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating expenses:
General and administrative	$ 1,201,734	$ 700,507
Research and development	1,319,020	629,531
Total operating expenses	2,520,754	1,330,038
Loss from operations	(2,520,754)	(1,330,038)
Other expense:
Interest income	27,892
Interest expense		(388)
Total other income (expense), net	27,892	(388)
Loss before provision for income taxes	(2,492,862)	(1,330,426)
Provision for income taxes	5,170	1,622
Net loss	(2,498,032)	(1,332,048)
Net loss attributable to non-controlling interests	18,368
Net loss attributable to Immix Biopharma, Inc. common stockholders	(2,479,664)	(1,332,048)
Other comprehensive income (loss):
Foreign currency translation	(4,474)	15,587
Total other comprehensive income (loss)	(4,474)	15,587
Comprehensive loss	$ (2,502,506)	$ (1,316,461)
Loss per common share - basic and diluted	$ (0.18)	$ (0.10)
Weighted average shares outstanding – basic and diluted	13,897,184	13,830,374